MX385305B - Composiciones de ribósido de nicotinamida para uso tópico en el tratamiento de afecciones de la piel. - Google Patents

Composiciones de ribósido de nicotinamida para uso tópico en el tratamiento de afecciones de la piel.

Info

Publication number
MX385305B
MX385305B MX2016005574A MX2016005574A MX385305B MX 385305 B MX385305 B MX 385305B MX 2016005574 A MX2016005574 A MX 2016005574A MX 2016005574 A MX2016005574 A MX 2016005574A MX 385305 B MX385305 B MX 385305B
Authority
MX
Mexico
Prior art keywords
nicotinamide riboside
treatment
compositions
skin conditions
skin
Prior art date
Application number
MX2016005574A
Other languages
English (en)
Other versions
MX2016005574A (es
Inventor
Ann Deren-Lewis
Troy Rhonemus
Original Assignee
Chromadex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc filed Critical Chromadex Inc
Publication of MX2016005574A publication Critical patent/MX2016005574A/es
Publication of MX385305B publication Critical patent/MX385305B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Birds (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cosmetics (AREA)

Abstract

Se proporcionan composiciones se contienen ribósido de nicotinamida (NR). Se utilizan composiciones que contienen NR para el cuidado o tratamiento de la piel y afecciones de la piel. En algunas realizaciones, la invención se refiere a composiciones farmacéuticas y composiciones cosméticas que contienen ribósido de nicotinamida. En realizaciones adicionales, la invención se refiere a métodos para utilizar ribósido de nicotinamida para promover el incremento de los niveles intracelulares del dinucleótido de nicotinamida y adenina (NAD+) en las células y los tejidos para mejorar la supervivencia de las células y los tejidos. Se proporciona un método para tratar las señales o síntomas del envejecimiento o arrugas de la piel en un individuo, que comprende administrar por vía tópica al individuo que necesite un tratamiento de este tipo una cantidad eficaz del compuesto ribosido de nicotinamida o sus sales.
MX2016005574A 2013-10-30 2014-10-30 Composiciones de ribósido de nicotinamida para uso tópico en el tratamiento de afecciones de la piel. MX385305B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361897713P 2013-10-30 2013-10-30
PCT/US2014/063260 WO2015066382A1 (en) 2013-10-30 2014-10-30 Nicotinamide riboside compositions for topical use in treating skin conditions

Publications (2)

Publication Number Publication Date
MX2016005574A MX2016005574A (es) 2016-12-09
MX385305B true MX385305B (es) 2025-03-18

Family

ID=53005146

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016005574A MX385305B (es) 2013-10-30 2014-10-30 Composiciones de ribósido de nicotinamida para uso tópico en el tratamiento de afecciones de la piel.
MX2021009652A MX394291B (es) 2013-10-30 2014-10-30 Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021009652A MX394291B (es) 2013-10-30 2014-10-30 Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.

Country Status (12)

Country Link
US (2) US10688118B2 (es)
EP (1) EP3063163B1 (es)
JP (1) JP6509844B2 (es)
KR (3) KR20210107895A (es)
CN (2) CN109985056A (es)
AU (1) AU2014342185B2 (es)
CA (1) CA2928656C (es)
ES (1) ES2925879T3 (es)
MX (2) MX385305B (es)
NZ (1) NZ719328A (es)
WO (1) WO2015066382A1 (es)
ZA (1) ZA201603314B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015270130A1 (en) * 2014-06-02 2016-12-15 Glaxosmithkline Intellectual Property (No.2) Limited Preparation and use of crystalline beta-D-nicotinamide riboside
JP6559713B2 (ja) 2014-06-06 2019-08-14 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ニコチンアミドリボシド類似体ならびにその医薬組成物および使用
WO2016014927A2 (en) 2014-07-24 2016-01-28 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
CN107428791B (zh) 2015-03-09 2024-05-28 格雷斯公司 烟酰胺核苷的结晶形式
MX390185B (es) 2015-03-16 2025-03-20 Chromadex Inc Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso.
JP6611099B2 (ja) * 2015-05-01 2019-11-27 ザ プロクター アンド ギャンブル カンパニー 皮膚の健康を改善する方法及びそのための組成物
JP2018515485A (ja) 2015-05-01 2018-06-14 ザ プロクター アンド ギャンブル カンパニー 皮膚の外観を改善する方法及びニコチンアミドリボシドを使用したそのための組成物
JP2018515486A (ja) 2015-05-01 2018-06-14 ザ プロクター アンド ギャンブル カンパニー ニコチンアミドリボシドを用いた皮膚外観の改善方法及びそのための組成物
JP2018517774A (ja) * 2015-06-10 2018-07-05 エリジウム・ヘルス・インコーポレイテッド ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法
US20180177703A1 (en) * 2015-06-25 2018-06-28 N.V. Perricone Llc Niacinamide Mononucleotide Formulations For Skin Aging
WO2017004100A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Encapsulated particles comprising nicotinamide riboside
WO2017004102A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container
WO2017004101A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Skin care compositions comprising particles with nicotinamide riboside and methods of using the same
EP3236928B1 (en) 2016-01-11 2020-12-09 The Procter and Gamble Company Method of treating a skin condition and compositions therefor
CA3017254C (en) 2016-03-16 2023-08-22 ChromaDex Inc. B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
WO2017184885A1 (en) * 2016-04-20 2017-10-26 ChromaDex Inc. Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors
AU2017316614B2 (en) 2016-08-22 2023-06-15 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders
AU2017356475B2 (en) 2016-11-11 2023-11-30 ChromaDex Inc. Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
WO2018102426A1 (en) 2016-11-29 2018-06-07 University Of Iowa Research Foundation Use of nad precursors for improving maternal health and/or offspring health
WO2018113634A1 (en) 2016-12-21 2018-06-28 Unilever Plc Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
US11077039B2 (en) 2016-12-21 2021-08-03 Conopco, Inc. Topical skin lightening additive and composition with amino acids and nicotinamide compounds
JP7082623B2 (ja) 2016-12-21 2022-06-08 ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ シスチンを有するパーソナルケア用組成物
CA3046721A1 (en) 2016-12-21 2018-06-28 Unilever Plc Personal care compositions comprising poorly soluble compounds
RU2651047C1 (ru) * 2017-05-04 2018-04-18 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Лекарственная композиция цитопротекторного действия и способ ее получения
WO2018213715A1 (en) * 2017-05-18 2018-11-22 Elysium Health, Inc. Methods and compositions for improving sleep
SG11201912267SA (en) 2017-06-19 2020-01-30 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
WO2018237218A1 (en) 2017-06-23 2018-12-27 The Procter & Gamble Company Composition and method for improving the appearance of skin
CN111542312A (zh) * 2017-07-28 2020-08-14 老龄化控制中心股份公司 预防和逆转衰老方面的组合物和方法
US11219590B2 (en) * 2017-09-14 2022-01-11 Megumi Tanaka Anti-aging agent and anti-aging method
GB201716391D0 (en) * 2017-10-06 2017-11-22 Xobaderm Ltd Kit for delivery of an active compound into a biological barrier
WO2019126482A1 (en) 2017-12-22 2019-06-27 Elysium Health, Inc. Crystalline forms of nicotinamide riboside chloride
EP3817717A1 (en) 2018-07-03 2021-05-12 The Procter & Gamble Company Method of treating a skin condition
CN110913864B (zh) * 2018-08-17 2022-12-13 邦泰生物工程(深圳)有限公司 一种稳定型烟酰胺核糖组合物及其制备方法
KR102060374B1 (ko) * 2018-12-14 2019-12-30 주식회사 휴메딕스 지방알코올 컨쥬게이션된 니코틴아미드 리보사이드 유도체
US11833167B2 (en) 2018-12-17 2023-12-05 Mitopower Llc Nicotinyl riboside compounds and their uses
CN119462782A (zh) * 2019-07-19 2025-02-18 生物合成股份公司 制备烟酰胺呋喃核糖苷盐的方法、烟酰胺呋喃核糖苷盐本身及其用途
CN110638827A (zh) * 2019-10-17 2020-01-03 泓博元生命科技（深圳）有限公司 Nadh及其盐在制备皮肤色素抑制剂中的应用
CN111166760A (zh) * 2019-12-17 2020-05-19 浙江安赛新材料科技有限公司 β-烟酰胺单核苷酸或其前体的组合物及制备方法、应用
KR102315139B1 (ko) 2019-12-17 2021-10-20 주식회사 휴메딕스 지방아민 컨쥬게이션된 니코틴아미드 리보사이드 유도체
CN111184732B (zh) * 2020-03-04 2023-09-08 武汉华纳联合药业有限公司 一种复合组合物制剂及其制备方法和皮肤炎症中的应用
CN111454311B (zh) * 2020-04-03 2021-10-19 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其组合物与制备方法
US20230210746A1 (en) * 2020-05-20 2023-07-06 Nuvamid Sa Anti-aging cosmetic compositions comprising nmn
FR3110410A1 (fr) * 2020-05-20 2021-11-26 Nuvamid Sa Compositions cosmétiques anti-âge comprenant de la NMN
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
JP7590462B2 (ja) 2020-06-01 2024-11-26 ザ プロクター アンド ギャンブル カンパニー ビタミンｂ３化合物の皮膚への浸透を改善する方法
CN111632049A (zh) * 2020-06-09 2020-09-08 西北农林科技大学 一种通过综合矫正细胞活性氧簇代谢紊乱以缓解睾丸衰老损伤的复合配方
US20230263817A1 (en) * 2020-08-28 2023-08-24 University Of Washington High dose nicotinamide adenine dinucleotide (nad) precursor regimens for reduction of inflammation in human patients with preexisting inflammation
JP7761652B2 (ja) * 2021-01-19 2025-10-28 バイオシント アクチェンゲゼルシャフト 塩メタセシスによるニコチンアミドリボフラノシド塩の製造方法、そのトシレート塩の結晶形態及びそのクロリド：ヨージド塩の共結晶化した形態
KR20240009434A (ko) * 2021-05-04 2024-01-22 소비다 솔루션즈 리미티드 니코틴아미드 아데닌 디뉴클레오티드 (nad) 조성물, 이의 제조 방법 및 이의 사용 방법
CN114129509B (zh) * 2021-12-03 2023-12-01 药酚享科技(北京)有限公司 一种保湿性nmn亲水凝胶剂及其制备方法
CN116621898A (zh) * 2022-04-13 2023-08-22 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其结晶形态、制备方法与用途
KR102784901B1 (ko) * 2022-06-23 2025-03-21 제너럴바이오(주) Nr, nmn 및 nad를 함유한 피부 주름 개선용 화장료 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100369602C (zh) * 2001-02-22 2008-02-20 荷兰联合利华有限公司 改进的皮肤用组合物
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
JP2007521835A (ja) 2004-02-10 2007-08-09 トラスティーズ・オブ・ダートマウス・カレッジ ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法
WO2006001982A2 (en) 2004-06-04 2006-01-05 Washington University Methods and compositions for treating neuropathies
EP1877054A2 (en) * 2005-03-30 2008-01-16 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
CN101257897A (zh) * 2005-07-07 2008-09-03 西特里斯药业公司 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物
EP1898897A2 (en) * 2005-07-07 2008-03-19 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
EP3730507A1 (en) 2005-11-18 2020-10-28 Cornell Research Foundation, Inc. Nicotinoyl riboside and nicotinamide riboside compositions for use in reducing toxicity induced by hmg-coa reductase inhibitors
US20100105638A1 (en) * 2007-03-12 2010-04-29 Kerstin Den-Braven Cosmetic compositions
US20090069444A1 (en) 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
JP5688376B2 (ja) * 2010-01-06 2015-03-25 株式会社ヤクルト本社 経口用のｄｎａ損傷修復促進剤及びエラスターゼ活性抑制剤

Also Published As

Publication number Publication date
KR20220098049A (ko) 2022-07-08
AU2014342185B2 (en) 2019-01-03
JP6509844B2 (ja) 2019-05-08
KR20160067195A (ko) 2016-06-13
US20200289536A1 (en) 2020-09-17
ES2925879T3 (es) 2022-10-20
JP2016538271A (ja) 2016-12-08
US11033568B2 (en) 2021-06-15
EP3063163B1 (en) 2022-08-10
CN105873937A (zh) 2016-08-17
US20160250241A1 (en) 2016-09-01
MX2016005574A (es) 2016-12-09
EP3063163A1 (en) 2016-09-07
KR20210107895A (ko) 2021-09-01
EP3063163A4 (en) 2017-05-10
CA2928656C (en) 2020-07-28
MX2021009652A (es) 2022-07-26
CN109985056A (zh) 2019-07-09
NZ719328A (en) 2022-04-29
MX394291B (es) 2025-03-24
US10688118B2 (en) 2020-06-23
CA2928656A1 (en) 2015-05-07
WO2015066382A1 (en) 2015-05-07
ZA201603314B (en) 2017-09-27

Similar Documents

Publication Publication Date Title
MX385305B (es) Composiciones de ribósido de nicotinamida para uso tópico en el tratamiento de afecciones de la piel.
BR112017019696A2 (pt) composto e usos de um composto
BR112014006455A2 (pt) alquilamidotiazóis, preparações cosméticas ou dermatológicas com um teor de um ou vários alquilamidotiazóis e uso de um ou vários alquilamidotiazóis
EA201890435A1 (ru) Производные никотинамидмононуклеотида и их применение
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
MX394252B (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf
CL2016000544A1 (es) Composición cosmética que comprende 0,0001 a 10% en peso de extracto de guacatonga (casearia sylvestris) y 0,00005 a 10% en peso de extracto de aroeira (schinus terebinthifolius raddi) ambos respecto al peso total de la composición; uso de la composición en la prevención y/o tratamiento de los signos de envejicimiento de la piel; metodo para prevenir y/o tratar los signos de envejecimiento de la piel.
ES2572211T3 (es) Regeneración de músculo esquelético utilizando células madre mesenquimales
BR112015007878A2 (pt) composto compreendendo oligonucleotídeo modificado, composição, combinação e uso dos mesmos
BR112016000335A8 (pt) método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica
BRPI0919020B8 (pt) uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
BR112015006790A2 (pt) composição de cetoprofeno tópico
RU2014150505A (ru) Способ идентификации лигандов рецептора ahr, которые обладают терапевтической себосупрессивной активностью, и указанные лиганды
BR112014003071A2 (pt) tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical
WO2012116990A3 (en) Novel use
AR083651A1 (es) Composiciones de brimonidina en gel y metodos de uso
CO6660486A2 (es) Composición tópica famacéutica o cosmética útil para el tratamiento de enfermedades o condiciones que cursan con un déficit de la maduración de la envoltura córnea
MX385999B (es) Composiciones y métodos para tratamiento de la piel.
BR112012015984A2 (pt) composição para melhorar a função cerebral, e, polipeptídeo
MX349854B (es) Composiciones antitranspirantes y metodo para reducir la transpiracion.
BR112012023747A2 (pt) compostos de adenosina e seu uso
BR112015002041A2 (pt) formulação transdérmica contendo inibidores de cox
UY34009A (es) ?uso de receptor de a2b adenosina para tratar la insuficiencia cardíaca y la arritmia en pacientes posinfarto de miocardio?.
AR097216A1 (es) Composición para el tratamiento contra el envejecimiento de la piel
CR20130488A (es) Derivados de tieno [2,3-d]pirimidina y su uso para tratar arritmia